Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines
Overview
Authors
Affiliations
Background: Comparison of humoral responses in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinees, those with SARS-CoV-2 infection, or combinations of vaccine/ infection ("hybrid immunity") may clarify predictors of vaccine immunogenicity.
Methods: We studied 2660 US Military Health System beneficiaries with a history of SARS-CoV-2 infection-alone (n = 705), vaccination-alone (n = 932), vaccine-after-infection (n = 869), and vaccine-breakthrough-infection (n = 154). Peak anti-spike-immunoglobulin G (IgG) responses through 183 days were compared, with adjustment for vaccine product, demography, and comorbidities. We excluded those with evidence of clinical or subclinical SARS-CoV-2 reinfection from all groups.
Results: Multivariable regression results indicated that vaccine-after-infection anti-spike-IgG responses were higher than infection-alone (P < .01), regardless of prior infection severity. An increased time between infection and vaccination was associated with greater post-vaccination IgG response (P < .01). Vaccination-alone elicited a greater IgG response but more rapid waning of IgG (P < .01) compared with infection-alone (P < .01). BNT162b2 and mRNA-1273 vaccine-receipt was associated with greater IgG responses compared with JNJ-78436735 vaccine-receipt (P < .01), regardless of infection history. Those with vaccine-after-infection or vaccine-breakthrough-infection had a more durable anti-spike-IgG response compared to infection-alone (P < .01).
Conclusions: Vaccine-receipt elicited higher anti-spike-IgG responses than infection-alone, although IgG levels waned faster in those vaccinated (compared to infection-alone). Vaccine-after-infection elicits a greater humoral response compared with vaccine or infection alone; and the timing, but not disease severity, of prior infection predicted these post-vaccination IgG responses. While differences between groups were small in magnitude, these results offer insights into vaccine immunogenicity variations that may help inform vaccination timing strategies.
Serological insights from SARS-CoV-2 heterologous prime and boost responses in Thailand.
Ward D, Pattarapreeyakul L, Pitaksalee R, Thawong N, Sawaengdee W, Tuntigumthon S Sci Rep. 2025; 15(1):1519.
PMID: 39789037 PMC: 11718049. DOI: 10.1038/s41598-024-84392-2.
Kusunoki H Vaccines (Basel). 2025; 12(12.
PMID: 39772074 PMC: 11680318. DOI: 10.3390/vaccines12121413.
Wang K, Zeng T, Guo Z, Liang J, Sun S, Ni Y BMC Infect Dis. 2024; 24(1):1401.
PMID: 39695978 PMC: 11654266. DOI: 10.1186/s12879-024-10250-1.
Wiegand R, Fireman B, Najdowski M, Tenforde M, Link-Gelles R, Ferdinands J Nat Commun. 2024; 15(1):10062.
PMID: 39567531 PMC: 11579392. DOI: 10.1038/s41467-024-54404-w.
Muehleman D, Gruner B, Hogan V, Fanning P, Garrett C, Meyer J Emerg Infect Dis. 2024; 30(14):53-61.
PMID: 39530855 PMC: 11559565. DOI: 10.3201/eid3014.240231.